Item no. |
LEIN-LT100-50mg |
Manufacturer |
Leinco Technologies
|
Amount |
50 mg |
Quantity options |
1 mg
100 mg
25 mg
5 mg
50 mg
Custom
|
Category |
|
Type |
Antibody Primary |
Applications |
FC, IF, IP, IHC, ELISA, FA, other |
Clone |
D2E7 |
Specific against |
Human (Homo sapiens) |
Host |
Human |
Purity |
≥98% monomer by analytical SEC, >95% by SDS Page |
Citations |
1. Omidinia, E. et al. (2019) Protein Expr Purif. 155:59-65. |
NCBI |
7124 |
ECLASS 10.1 |
32160702 |
ECLASS 11.0 |
32160702 |
UNSPSC |
12352203 |
Shipping condition |
Cool pack |
Available |
|
Manufacturer - Applications |
Quality Tested by Leinco FC The suggested concentration for Adalimumab biosimilar antibody for staining cells in flow cytometry is ≤ 0.25 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. |
Manufacturer - Category |
Recombinant Antibodies>Biosimilar Recombinant Antibodies |
Manufacturer - Targets |
TNF alpha |
Country of Origin |
USA |
Shipping Temperature |
2 - 8°C Wet Ice |
Storage Conditions |
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles. |
Product Description |
Adalimumab is a research-grade monoclonal antibody that works by inactivating tumor necrosis factor-alpha (TNF-α). TNF-α is a 17.5 kD protein that mediates inflammation and immunity caused by the invasion of viruses, bacteria, and parasites by initiating a cascade of cytokines that increase vascular permeability, thus bringing macrophages and neutrophils to the site of infection. TNF-α secreted by the macrophage causes the blood to clot which provides containment of the infection. TNF-α inactivation has proven to be important in downregulating the inflammatory reactions associated with autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, moderate to severe chronic psoriasis, and juvenile idiopathic arthritis. Adalimumab blocks the interaction with the p55 and p75 cell surface TNF receptors thus, neutralizing the biological function of TNF. Anti-Human TNF alpha (Adalimumab) utilizes the same variable regions from the therapeutic antibody Adalimumab making it ideal for research projects. |
Background |
Adalimumab is a research-grade monoclonal antibody that works by inactivating tumor necrosis factor-alpha (TNF-α). TNF-α is a 17.5 kD protein that mediates inflammation and immunity caused by the invasion of viruses, bacteria, and parasites by initiating a cascade of cytokines that increase vascular permeability, thus bringing macrophages and neutrophils to the site of infection. TNF-α secreted by the macrophage causes the blood to clot which provides containment of the infection. TNF-α inactivation has proven to be important in downregulating the inflammatory reactions associated with autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, moderate to severe chronic psoriasis, and juvenile idiopathic arthritis. Adalimumab blocks the interaction with the p55 and p75 cell surface TNF receptors thus, neutralizing the biological function of TNF. Anti-Human TNF alpha (Adalimumab) utilizes the same variable regions from the therapeutic antibody Adalimumab making it ideal for research projects. |
Pathogen Testing |
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. |
Other Applications Reported In Literature |
N B ELISA FA IF IP IHC |
PubMed |
TNF alpha |
Manufacturer - Expression host |
HEK-293 |
Manufacturer - Specificity |
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Adalimumab. Clone D2E7 binds to soluble TNF- α, but not to TNF- β (lymphotoxin). This product is for research use only. |
FC Effector Activity |
Active |
RRID |
AB_2893873 |
Concentration |
≥ 5.0 mg/ml |
Formulation |
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. |
Product Preparation |
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. |
Antigen Distribution |
TNF-α is secreted by macrophages, monocytes, neutrophils, T cells, B cells, NK cells, LAK cells. |
Endotoxin Level |
≤ 1.0 EU/mg as determined by the LAL method |
Immunogen |
Human TNF alpha |
Regulatory Status |
Research Use Only (RUO). Non-Therapeutic. |
Additonal Information |
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. |
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.